iPSC-derived CD16/IL-15RF-expressing anti-CD19 CAR-NK cells FT596

{
  "id": "MLC-T-ONC-014562",
  "term": "iPSC-derived CD16/IL-15RF-expressing anti-CD19 CAR-NK cells FT596",
  "field": "Oncology and biomedicine",
  "definition": "An allogeneic, off-the-shelf, chimeric antigen receptor (CAR)-natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a NK cell-specific anti-CD19 CAR, a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF), with potential immunostimulatory and antineoplastic activities. Upon administration, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15RF enhances the cytotoxic effect of the NK cells and the activated anti-tumor T-cells. When used in combination with monoclonal antibodies, the hnCD16 Fc receptor of FT596 binds to the Fc portion of tumor cell-bound monoclonal antibodies, leading to NK cell activation, cytokine secretion and enhanced antibody-dependent cellular cytotoxicity (ADCC). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response.",
  "synonyms": [
    "iPSC-derived CD16/IL-15RF-expressing anti-CD19 CAR-natural killer cells FT596",
    "induced pluripotent stem cell-derived CD16/IL-15RF-expressing anti-CD19 CAR-NK cells FT596"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ipsc-derived-cd16-il-15rf-expressing-anti-cd19-car-nk-cells-ft596/"
}